NEW YORK (GenomeWeb) – Molecular diagnostics firm Bioarray Genetics on Thursday said that it has received $4 million in Series B equity financing.

The funding came from Quark Venture and GF Securities through their Global Health Science Fund and Connecticut Innovations, and will be used to move Bioarray Genetics' first product, BA100, a breast cancer diagnostic, to clinicians. The financing will also be used for R&D for other tests, including those targeting treatments for metastatic breast and colon cancers, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.